Drug intelligence / Profile preview

ct3001

Development stage: Phase 2
Lead developer: Crossignal Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

CT3001 is a first-in-class, orally administered small molecule inhibitor of G-protein coupled receptor 35 (GPR35). It is formulated as an oral solution with PEG 400, strawberry flavor, and anhydrous ethanol. CT3001 targets GPR35, which is an oncogenic GPCR found to be overexpressed in various solid tumors. By inhibiting GPR35-driven Yes-associated Protein (YAP) oncogene activation—a pathway implicated in tumorigenesis and immune escape—CT3001 aims to suppress tumor growth and enhance anti-tumor immunity. The drug is being developed primarily for the treatment of advanced solid tumors including colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and other related malignancies[1][2][3][4].

Other names: CT-3001CT3001CT 3001

Targets

GPR35 (G-protein Coupled Receptor 35)

Beyond the preview

Go deeper on ct3001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ct3001.

Explore the full profile